Central Role For Industry Beckons As Europe Rebuilds After COVID
Generics And Biosimilars Must Become A Central Policy Pillar, Says Rebecca Guntern
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.
You may also be interested in...
Countries across Central and Eastern Europe are failing to reap the full benefit of generic and biosimilar competition, according to a new report from Medicines for Europe.
As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
Last year was a year of significant executive changes in the off-patent industry, with numerous high-profile hires and departures from companies like Sandoz, Teva, Viatris, Hikma, Fresenius, Neuraxpharm and Stada.